StreetAlpha.app
Home › Stocks › ENLV

Enlivex Ltd. (ENLV)

$1.17
▲ +6.36%
LAST CLOSE · NOV 17

Enlivex develops Allocetra, a therapy for knee osteoarthritis, and holds RAIN tokens in its treasury. It last closed at $1.17 on Nov 17, up 6.36% on the day. ENLV last reported earnings on Fri, Sep 18, 2026.

AI Auto Pilots
Is ENLV in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
$1.2B
Balance sheet
Cash & equivalents
$1.9M
At Dec 31
Shareholder equity
$1.9B
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$14.5M−$14.5MFY2021FY2022: −$31.1M−$31.1MFY2022FY2023: −$29.1M−$29.1MFY2023FY2024: −$15.0M−$15.0MFY2024FY2025: $1.2B$1.2BFY2025

From ENLV's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 25). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Last report
Sep 18
2026 · Time not announced
Reported EPS
-$1.20
vs -$0.31 est. · miss
Year-ago EPS
-$1.20
Same quarter last year
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated ENLV in the past 90 days.
Average 12-month target
No price targets on ENLV in the past 90 days.
Latest rating changes
HC Wainwright & Co.Maintained
Aug 3Buy$80
DateFirmActionRatingPrice target
Aug 3HC Wainwright & Co.MaintainedBuy$80
Loading…

Technical Analysis

ENLV · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 57% below its 20 day and 391% below its 50 day average. It is 10525% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 16), oversold. The nearest support is the Pivot at $1.15, and the nearest resistance the Pivot R1 at $1.20.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 39.9%/day
Key levels
$434.4052 week high+37028.2%
$124.31200 day average+10524.8%
$30.83100 day average+2535.0%
$6.88Swing high (Oct 8)+488.0%
$5.7450 day average+390.6%
$1.8420 day average+57.3%
$1.20Pivot R1+2.6%
$1.17Last close
$1.15Pivot−1.7%
$1.13Pivot S1−3.4%
$1.0052 week low−14.5%
Indicators
RSI (14)15.69Oversold below 30Oversold
MACD-1.58Above its signal lineBullish
Stochastic5.5Near the bottom of its rangeOversold
ADX (14)68.3Strong downtrend
Williams %R-90.3Oversold below −80, overbought above −20Oversold
CCI (20)-69.6Oversold below −100, overbought above 100Neutral
Rate of change−19.9%Change over 10 sessionsBearish
ATR (14)$0.47Typical daily range, 39.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ENLV

What happened before

See how ENLV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ENLV usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ENLV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ENLV in the last 90 days.

Loading…

See today’s whale options flow across the market →

ENLV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼17 buying vs 24 selling
  • ▼Shares held by funds -91.1%
  • ▼Funds holding -8
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding1725−32.0%
In funds' top 1000–
Held by funds–––
New / increased17 / 05 / 9+21.4%
Reduced / sold out0 / 247 / 13+20.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ENLV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENLV is in one of them and how their past ENLV trades turned out.

ENLV in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ENLV in an article yet. Here's the latest on the wider market.

About Enlivex

Enlivex is a drug development company based in Tel Aviv. It is developing Allocetra, a therapy designed to rebalance the immune system, and is testing it as a possible treatment for knee osteoarthritis, a joint condition linked to aging. The company also holds a treasury of RAIN, the governance token of a decentralized prediction markets platform built on the Arbitrum network.

Headquarters
Tel Aviv